This inventor holds 1 USPTO granted patent. Top assignee: Neurogen Corporation. Active years: 2002.
Company Filing History:
Years Active: 2002
Title: Salva Terdjanian: Innovator in Dopamine Receptor Research
Introduction
Salva Terdjanian is a notable inventor based in New Britain, Connecticut. He has made significant contributions to the field of pharmacology, particularly in the development of dopamine receptor subtype specific ligands. His work is essential for advancing our understanding of neuropharmacology and potential therapeutic applications.
Latest Patents
Salva Terdjanian holds a patent for "Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands." This patent highlights his innovative approach to creating compounds that can selectively target specific dopamine receptors, which is crucial for developing new treatments for various neurological disorders. He has 1 patent to his name.
Career Highlights
Terdjanian is currently employed at Neurogen Corporation, a company dedicated to discovering and developing innovative therapies for neurological and psychiatric disorders. His role at Neurogen allows him to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Throughout his career, Salva has worked alongside talented colleagues, including Andrew Y. Thurkauf and Renata Xavier Kover. These collaborations have fostered a productive environment for innovation and research in the field of neuroscience.
Conclusion
Salva Terdjanian's work exemplifies the impact of innovative research in the field of pharmacology. His contributions to dopamine receptor research are paving the way for future advancements in therapeutic options for neurological conditions.